Warning letter
Shadow Holdings DBA Bocchi Labs: warning letter of Feb 6, 2019
FDA warning letter 561273 · Los Angeles District Office
Key facts
| Reference number | 561273 |
|---|---|
| Company | Shadow Holdings DBA Bocchi Labs |
| Subject | Cosmetics/Adulterated |
| Issue date | Feb 6, 2019 |
| Posted date | Feb 26, 2019 |
| Issuing office | Los Angeles District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 211.34, 211.22(a) |
| Inspection city | Santa Clarita |
| Inspection ZIP | 91350 |
| Inspection start date | Mar 29, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: